Category: ACN Newswire

香港，2025年7月28日 - (亞太商訊 via SeaPRwire.com) - 7月24日，中國再保險（香港）股份有限公司[以下簡稱"中再壽險（香港）"]主辦的優質醫療-無界溝通-粵港澳大灣區醫療保險發展論壇在香港舉行，並聯合母公司中國人壽再保險有限責任公司（以下簡稱"中再壽險"）正式發佈首款大灣區跨境醫療創新產品方案（以下簡稱"產品方案"）。依託國家政策指引和專業技術賦能，該產品方案突破跨境商保結算、特藥智能理賠、醫療信息壁壘等關鍵節點，打造全週期的"港人北上"醫療保障方案，與香港本地產品形成錯位互補，推動大灣區醫療保障互聯互通領域取得突破性進展。國務院《粵港澳大灣區發展規劃綱要》指出"推動粵港澳三地優質醫療衛生資源互聯互通，支持粵港澳保險機構合作開發創新型跨境醫療保險產品"。本次發佈會積極響應建設"健康灣區"號召，發揮再保險平台和資源鏈接優勢，匯聚了來自香港壽險、財險、再保、再保經紀等公司領導以及醫療、製藥、投資等領域權威專家，聚焦粵港澳大灣區跨境醫療保險融合發展建言獻策。中再壽險（香港）行政總裁羅亞偉在大會致辭中表示，中再壽險（香港）以民族再保險企業的為民初心、服務國家戰略的堅定決心以及與行業和生態夥伴共贏發展的誠摯真心，破解痛點，研發大灣區跨境醫療創新產品，以期為居民跨境醫療帶來革命性便利，為"健康灣區"貢獻堅實力量。作為本次會議的重要議題，首款大灣區跨境醫療創新產品方案重磅發佈。中再壽險產品開發部總經理助理王明彥對於產品形態和核心優勢進行瞭解讀。中再壽險作為內地商業醫療險的領軍者，憑藉在醫療產品創新、"三醫聯動"領域的深厚積澱、海量數據優勢及領先的科技風控手段，精准洞察"港人北上"就醫需求與政策機遇，深度整合內地與香港醫療資源優勢，針對性研發出此跨境醫療解決方案。新產品主要聚焦香港本地中等收入人群及內地居港新移民，為其提供獨立、高性價比的內地住院醫療保障，並深度整合內地優質醫療資源與服務網絡，兜底大病風險，打通港人北上就醫關鍵節點，顯著提升服務體驗。後續也可以針對不同保司的需求，進行定制化方案設計，誠邀各位合作夥伴共同合作、共建灣區。在全場嘉賓的見證下，中再壽險（香港）、中銀人壽、中銀集團保險、太平人壽（香港）、太平保險（香港）和鎂信健康公司等相關負責人，共同發佈"服務國家戰略，共建健康灣區"倡議。這一標誌性時刻，宣告"保險+健康+醫療科技"融合創新模式落地香港國際金融中心。圓桌論壇環節中來自保險、醫療等各界嘉賓，聚焦產品創新攻堅、科技賦能升級、產業生態融合和政策研究等話題積極建言獻策。特別是針對大灣區醫療資源發展還需更加平衡、跨境醫療創新還需進一步樹立客戶信心、跨境融合的上下游執行標準還需進一步統一等關鍵問題展開討論，也為未來行業共同打造"灣區一小時健康生態圈"提供了攻堅方向。大會最後，中再壽險（香港）董事長李明在總結發言中表示，論壇在服務人民健康開啟跨境醫療創新里程碑、服務市場需求攜手共贏促進行業發展、拓展產業生態圈開放協同推動跨領域合作三個方面取得了超過預期的成果，進一步凝聚起各界共識。期待各位夥伴攜手同行，用專業與誠意澆灌"跨境醫療創新"種子，共同迎接粵港澳大灣區醫療健康碩果滿枝的明天。目前，中國再保險（集團）股份有限公司已成立粵港澳大灣區協同發展工作組，依託遍佈廣東全省分支機搆，以及中再資產（香港）、中再壽險（香港）兩個平台，錨定服務健康養老、實體經濟、新質生產力等重點方向。下一步，中再壽險（香港）將以跨境醫療保險為突破口，推動"港人北上"醫療、養老便利化；提升資產負債協同效能，支持內地與港澳保險機構開展保險產品跨境交易和跨境人民幣再保險業務；推動海外特藥保險等一批國內優秀保險方案"走出去"，為服務粵港澳大灣區戰略貢獻再保智慧和力量。 Copyright 2025 亞太商訊 via SeaPRwire.com.

上海，2025年7月28日 - (亞太商訊 via SeaPRwire.com) - 2025年7月26日，中信國際電訊集團有限公司（股份代號：1883）攜旗下澳門電訊（CTM）、中信國際電訊CPC、中企通信等多家子公司，連續第四年在中信集團的統一部署下亮相2025世界人工智能大會。中信國際電訊緊扣本屆大會「智能時代 同球共濟」主題，以中信集團「要出國、找中信，來中國、找中信」服務品牌為引領，聚焦「智鏈國際 服務全」戰略方向，全面展示在人工智能技術與大模型發展領域的前沿探索，呈現在推動企業智能化升級、加速數字經濟互聯互通、強化企業「走出去」與「引進來」雙循環支撐體系、以及推動AI技術與產業場景深度融合等多方面的創新實踐與突破性成果。中信國際電訊正持續發揮橋樑紐帶作用，深度參與全球科技生態建設，助力企業「走出去」 、「引進來」 ，為全球智能科技發展注入新動能。 「智慧中信 共創新可能」本屆大會，中信集團以「智慧中信 共創新可能」為主題重磅亮相，依託「科技-產業-金融」循環聯動的綜合優勢，集中呈現了在科技創新、新興產業、金融賦能及國際化等領域的AI前沿應用與行業解決方案。作為中信集團新消費板塊的關鍵組成部分，中信國際電訊重點參與了集團展區「科技創新」與「國際化」兩大主題區域的展示，充分發揮旗下子公司協同優勢，強化技術底座支撐、產業賦能和生態協同，全力釋放 AI 高質量發展動能，為數字中國建設及全球數字經濟互聯互通貢獻中信智慧和中信方案。與此同時，中信國際電訊還在展區現場開展多場「中信AI+實踐分享」互動演示，向業界生動呈現這些創新成果的實踐價值與應用潛力。 「智鏈」國際，服務全球，燃動高質量發展「新引擎」全球數字經濟迅猛發展，中信國際電訊作為中信集團國際化業務的重要支撐力量，積極踐行國家「人工智能+」與高水平對外開放戰略部署，致力構建全球互聯的數智生態體系，持續拓展「走出去」、「引進來」雙向通道，打造開放、互信、共贏的全球數字生態。為實現這一戰略目標，中信國際電訊已在全球五大洲部署了豐富資源，近170個網絡服務節點、21座雲平台、30+數據中心及3座全天候運營的安全運作中心（SOCs），構建起全球範圍內覆蓋廣泛、響應敏捷的數智雲網安服務。不僅「智鏈」央國企及中資企業的全球安全連接需求，並為眾多外資跨國機構提供敏捷可靠的本地化智能雲網安服務，成為連接國際與本土、產業與科技的關鍵橋樑。此外，中信國際電訊也進一步深化區域協同與屬地化運營能力。旗下子公司ACCLIVIS深耕東盟市場，積極推動AI、雲網安全等技術在醫療、製造等領域應用，為南向通道注入源源不斷的創新動能；在港澳及大灣區，澳門電訊（CTM）深度參與「智慧澳門」建設，聚焦助力澳門經濟適度多元發展，推動智慧政務、智慧校園、智慧轉型等領域，成功打造出AI+通信技術融合的區域協同項目，為區域高質量發展提供強有力的數智支撐。截至目前，中信國際電訊已累計賦能3000餘家中外企業跨境發展，服務全球超過4萬家本地客戶，其中包括200餘家世界500強企業，切實將「全球戰略」規劃圖轉化為實景圖，攜手合作夥伴，共築智能互聯的數字未來。科技引領，聚勢賦能，「智鏈」未來新篇章中信國際電訊不斷夯實技術創新根基，打造面向未來的企業級數字能力底座，構建全球互聯數字新生態。公司憑藉深厚的技術積累與創新研發體系，圍繞AI+大數據、AI+網絡、AI+大模型應用等核心方向，持續推出可規模化複製的落地方案。在AI數據治理領域，「AI Databank智數庫」數據智能平台深度融合大數據、AI、大語言模型（LLM）和生成式AI技術，構建統一數據平台，成功打破數據孤島，實現多業務系統數據的無縫整合，已在多行業中實現廣泛應用。憑藉其突破性的人工智能數據治理技術與前瞻的實用價值，AI Databank更是獲得了2025年「第50屆日內瓦國際發明展覽會銀獎」，這一國際權威認證彰顯了中信國際電訊在AI賽道科研與創新的優秀能力。在網絡服務領域，「AI智能加速包」通過優化網絡路由和節點，顯著提升跨國企業全球數據傳輸效率和穩定性，結合先進數智技術與GSMA Open Gateway國際標準，已成功應用於港澳智慧旅遊場景，獲得了「Open Gateway全球應用場景設計開發大賽三等獎」的殊榮。在智賦民生領域，中信國際電訊展示了澳門電訊「智慧城市」 方案及萬兆網絡基建發展。澳門電訊率先以F5G-A與5G-A雙擎技術為基座 ，實現千兆網絡澳門全域覆蓋，並建成澳門首個「萬兆小區」，打造更多智能應用場景，推動公共服務和城市管理的數字化轉型，塑造「科技以人為本」的可持續未來。項目斬獲多個國內國際一流獎項，彰顯「數字澳門」與「科技強國」的同頻共振。憑藉AI技術的全生命周期服務能力，中信國際電訊正在逐步建立起從底層基礎設施到上層應用的完整創新鏈條，為產業的數智轉型提供強有力支撐，助力企業在全球化進程中贏得競爭優勢。合規護航，數據強基，「智鏈」 可信數字世界技術創新推動企業邁向全球化新高度，但數據安全與合規風險亦隨之凸顯。中信國際電訊積極響應國家《數據安全法》、《個人信息保護法》，並對接歐盟GDPR、東南亞PDPA等國際標準，前瞻布局AI時代的數據安全與合規服務體系，重點解決跨境數據傳輸、信息存取保障及金融風控等關鍵挑戰，為構建「 智能可信「 的數字世界提供全棧式安全保障。智匯未來，中信國際電訊在「中信AI+實踐分享」環節，聚力分享多個融合「科技-產業-金融」三大領域的輕量化AI+應用項目，致力以數智技術服務全球企業。《AI賦能金融防欺詐項目》聚焦金融安全領域。在跨境交易中，金融防欺詐已成為保障交易安全的關鍵一環。中信國際電訊推出的「AI賦能金融防欺詐解決方案」通過多層次的身份驗證與實時交易監控，有效防止跨境交易中的欺詐行為，保障金融機構和用戶資產安全，展現數字金融領域創新實力。《智鏈｜安全重啟，精準智析》專註於新一代網絡安全防護體系的建設。中信國際電訊構建了全方位、多層次的智能安全防禦矩陣，AI Pentest智能滲透測試系統通過模擬攻擊與漏洞掃描，實現對潛在安全隱患的主動識別和修復，助力企業有效防範外部威脅與信息泄露風險；配合三個自建、自營、自管的AI-SOC智能安全運營中心，依託機器學習算法和大數據分析能力，整合AI大模型技術，提供實時威脅監測與自動化應對能力，為企業構建強韌的安全屏障；「AI安全圍欄」則覆蓋從終端到傳輸層的各關鍵節點，有效阻斷非法訪問、跨境數據泄露等安全風險。《智鏈｜從技術賦能到數據賦能》以數據治理與價值挖掘為核心。中信國際電訊通過創新專利技術、智能算法與大數據分析，協助企業實現安全高效的數據治理、跨系統整合及智能分析報告生成。同時賦能企業快速利用大模型技術，多元化小場景應用，處理數據收集、監測與合規報告。通過統一數據平台，以創新技術重塑企業級數據治理架構。面向未來，中信國際電訊將繼續以「鏈接」為本、以「智鏈」為要，依託中信集團的金融、科技與產業協同優勢，持續加大AI領域投入，推動更多「可用、可管、可信」的技術成果轉化落地，在智能時代的全球合作浪潮中，擔當中國企業高水平開放與科技出海的重要橋樑。相約H2館A308展區路漫漫其修遠兮，吾將上下而求索。面向數智時代的滾滾浪潮，科技創新是企業應變的核心引擎，更是國家發展的底氣。中信國際電訊正加快技術布局，以AI、大數據、雲計算、網絡安全等為支點，持續拓展「科技+」的全球版圖。我們期待與各方同仁攜手同行，智啟未來，共創共贏。「中信AI+實踐分享」詳情, 請參閱: https://mp.weixin.qq.com/s/svkprkpnnoC04gdsKZh9HA關於中信國際電訊集團有限公司（股份代號：1883）中信國際電訊集團有限公司於1997年在香港成立，並於2007年4月3日在香港聯合交易所上市。中信國際電訊作為亞太最大的國際電訊樞紐之一，為全球運營商客戶提供全面的國際電訊服務，並透過全資附屬公司Acclivis Technologies and Solutions Pte. Ltd.，在東南亞提供一站式跨區域企業服務。中信國際電訊全資附屬公司中信國際電訊（信息技術）有限公司（「CPC」）為全球跨國企業客戶和商業客戶提供一站式信息及通訊解決方案，CPC是亞太區跨國企業及商業客戶最可信賴的主要合作夥伴之一，同時透過附屬公司中企網絡通信技術有限公司，為中國內地大型企業及跨國商業客戶提供全方位ICT服務。中信國際電訊持有澳門電訊有限公司（「澳門電訊」）99%權益。澳門電訊是澳門主要的綜合電訊服務供貨商之一，亦是澳門唯一提供全面電訊和ICT服務的供應商，具市場領先地位，對澳門的持續發展舉足輕重。本集團在全球22個國家和地區設有分支機構，擁有約2,500位員工，全球網絡節點近170個、業務覆蓋達160個國家和地區，連接世界上600多家運營商，服務3,000多家跨國企業以及4萬餘家當地企業。中國中信集團有限公司為一家總部設於中國的大型綜合性跨國企業集團，是本公司的最終控股公司。如欲索取更多數據，請瀏覽以下網址：www.citictel.com。新聞垂詢：中信國際電訊李凱雯小姐電話：+852 3423 3168電郵：sylviali@citictel.com中信國際電訊CPC阮穎珊小姐電話：+852 2170 7536電郵：catherine.yuen@citictel-cpc.com Copyright 2025 亞太商訊 via SeaPRwire.com.

土耳其安卡拉，2025年7月29日 - (亞太商訊 via SeaPRwire.com) - GEN製藥公司（GENIL.IS）是土耳其領先的專業製藥公司，日前宣布其第一階段臨床試驗取得積極結果。該試驗旨在評估首創且新型的口服線粒體靶向候選藥物 SUL-238 在健康老年志願者中的安全性、耐受性以及藥代動力學（PK）表現。研究結果已在2025年阿茲海默症協會國際會議（AAIC®）上於多倫多公佈。本次第一階段臨床試驗為首個人體試驗，採用單次口服遞增劑量（SAD）設計，隨機、雙盲、安慰劑對照，共分為三個部分，納入了共計53名健康老年志願者。第一部分包括6個劑量組（口服劑量分別為50、100、250、500、1000和2000毫克，n=23）。第二部分中，研究了單劑1000毫克口服劑量在10名健康老年人的藥代動力學特徵。第二部分B評估了食物的影響，採用隨機、單劑2000毫克口服、雙處理、雙週期交叉設計（n=20）。試驗結果顯示，50至2000毫克的單次口服劑量 SUL-238 在受試者中均表現出良好的安全性和耐受性，同時具備良好的藥代動力學特徵，並能良好地滲透至腦脊液（CSF）。這些結果使得 SUL-238 成為治療包括阿茲海默症在內的神經退行性疾病的具前景的臨床開發候選藥物。未觀察到任何不良反應（AEs）限制劑量遞增，SUL-238組與安慰劑組的不良事件發生率相當，且所有不良事件均為輕度或中度。平均終末消除半衰期為0.86至3.80小時，達峰時間為0.50至1.39小時。在進食狀態下，血漿藥物最大濃度（Cmax）和血漿濃度-時間曲線下面積（AUC0-∞）分別下降了50%和60%。給藥後2小時和8小時腦脊液與血漿的濃度比例分別為21.1%（±6.6%）和74.2%（±46.0%）。GEN董事長 Abidin Gülmüş 表示：「這些令人鼓舞的首次人體試驗結果為我們帶來了極大信心，標誌著我們在應對阿茲海默症潛在生物機制方面邁出了重要一步。」GEN研發副總裁、醫學博士兼博士 Nadir Ulu 補充道：「在本次第一階段試驗中，SUL-238 展現出優異的安全性和藥代動力學特徵，結合扎實的臨床前數據，使其成為未來臨床開發的有力候選藥物，有望滿足包括阿茲海默症在內的神經退行性疾病領域亟待解決的臨床需求。」關於 SUL-238SUL-238 是一種首創的新型小分子藥物，其源自冬眠機制，靶向細胞的「能量工廠」——線粒體。該藥物通過激活線粒體複合體 I 和 IV 來支持線粒體的生物能量代謝，並已在神經退行性疾病、心血管疾病、腎臟疾病及衰老的囓齒動物模型中顯著改善線粒體功能。SUL-238 能穿越血腦屏障，並已在臨床前研究和第一階段試驗中完成了廣泛的安全性評估。GEN 獲得了 Sulfateq BV 授權，可將 SUL-238 應用於神經退行性疾病的治療開發。關於 GENGEN 成立於1998年，是土耳其領先的專業製藥公司，致力於在多個治療領域開發創新療法。GEN 擁有符合 GMP 認證標準的生產設施，生產高品質且具市場競爭力的藥品，並通過兩個專屬研發中心及研發投資推動原創藥物開發。關於 SulfateqSulfateq B.V. 是一家位於荷蘭的早期生物技術公司，致力於與學術界和產業研究中心開展戰略合作，以加速創新藥物的開發。該公司開發了一類新型小分子化合物——SUL 系列藥物，旨在維持線粒體健康功能。欲了解更多資訊:www.genilac.com.trwww.sulfateqbv.com聯絡資訊Bulutay Güneş企業品牌資深主管b.gunes@genilac.comAli Ketencioglu投資人關係經理a.ketencioglu@genilac.comKees van der GraafSulfateq 執行長info@sulfateqbv.com Copyright 2025 亞太商訊 via SeaPRwire.com.

SHENZHEN, CHINA, July 29, 2025 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that on 28 July 2025, the New Drug Application (NDA) for improved new drug ZUNVEYL (Benzgalantamine Gluconate Enteric-coated Tablets) (“ZUNVEYL” or the “Product”) has been accepted by the National Medical Products Administration of China (NMPA). The Product is indicated for the treatment of mild-to-moderate dementia of the Alzheimer’s type in adults.About Product ZUNVEYLZUNVEYL was approved in July 2024 by the U.S. Food and Drug Administration (FDA) for the treatment of mild-to-moderate dementia of the Alzheimer’s type in adults. As a new generation of acetylcholinesterase inhibitor (AChEI), ZUNVEYL can inhibit the acetylcholinesterase from breaking down the neurotransmitter acetylcholine, increase the level of acetylcholine in the central nervous system, and therefore alleviate cognition and memory impairment in Alzheimer’s disease patients. As a prodrug of galantamine, ZUNVEYL remains inert as it passes through the stomach and the intestine, and eventually releases the active drug into the bloodstream after being metabolized by the liver. With such a mechanism of action, ZUNVEYL is expected to have equivalent efficacy as galantamine with the potential of reducing gastrointestinal (GI) side effects and addressing certain tolerability issues. Galantamine has accumulated extensive evidence of efficacy and demonstrated long-term clinical benefit in the treatment of mild-to-moderate dementia of the Alzheimer’s type since the approval of FDA in 2001[1]. Moreover, GI adverse events documented across all studies for ZUNVEYL were less than 2% and no insomnia was observed[2]. As the second oral therapy approved by FDA for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better gastrointestinal safety profile to improve compliance of Alzheimer’s disease patients and therefore brings clinical benefits. Patent in regard to use of ZUNVEYL has already been granted in China.About Alzheimer’s DiseaseAlzheimer’s disease is a chronic, progressive neurodegenerative disease characterized by progressive decline in memory and other cognitive functions, among which some of the patients will progress to dementia. Dementia is a kind of syndrome with acquired cognitive function impairment as the core symptom, and can lead to the reduction of patients’ daily living, learning, working and social interaction ability. Alzheimer dementia accounts for 50% to 70% of all types of dementia[3,4]. According to the epidemiological study results published in the Lancet Public Health[5], there are about 9.83 million patients with Alzheimer dementia in China, of which 7.93 million are mild-to-moderate[6]. With the intensifying aging trend, the number of patients and the consequent disease burden will further increase in the future.Currently the clinical treatment of Alzheimer’s disease can be categorized as improving cognitive symptoms and decelerating disease progression[7], and AChEI belongs to the former. According to the Research Report on the Diagnosis and Treatment of Alzheimer’s disease Patients in China[8], the high incidence of side effects is one of the major pain points for existing drugs for Alzheimer’s disease, and drug intolerance is one of the challenges in current treatment of Alzheimer’s disease. Tolerability affects therapy adherence, with data showing that 55% of Alzheimer’s disease patients discontinue their medication after one year, mainly due to GI side effects and insomnia. Medication discontinuation can cause risk to patients themselves, and dissatisfaction and burden among patient’s family, physicians, and caregivers[9]. Therefore, Alzheimer’s disease patients still have an urgent need for safer therapies.On 8 January 2025, the Group through a wholly-owned subsidiary of the Company entered into a License, Collaboration and Distribution Agreement (the “Agreement”) with Alpha Cognition Inc. (“Alpha”) of the improved new drug ZUNVEYL for the treatment of mild-to-moderate dementia of the Alzheimer’s type. In accordance with the Agreement, the Group is entitled to an exclusive right to develop, register, manufacture, import, export and commercialize the Product in Asia (excluding Japan and the Middle East region), Australia and New Zealand (the “Territory”), Alpha reserves the right to manufacture and supply in the Territory. The term of cooperation commences on the effective date of the Agreement and extends for twenty years (the “Initial Term”), it may be automatically renewed every five years upon the expiration of the Initial Term unless terminated by notice from either party.Around six months after obtaining the above rights of ZUNVEYL, the Group promptly submitted the NDA in China, demonstrating its efficient allocation of resources and robust capabilities in registration promotion. ZUNVEYL will further diversify the Group’s innovative drug product matrix and enhance the Group’s comprehensive competitiveness. The Product will synergize with the Group’s various central nervous system products including the innovative drug VALTOCO (diazepam nasal spray) and the original brand drug Deanxit (flupentixol and melitracen tablets) on sale and the innovative drug Y-3 for Injection under development in terms of expert network and market resources. Relying on the Group’s successful commercialization experience and compliant and efficient commercialization system, if ZUNVEYL is approved for marketing, it will bring a new drug option for the treatment of cognitive impairment in Chinese Alzheimer’s disease patients, meeting the clinical need for drugs of both efficacy and safety, improving disease diagnosis and treatment practices, thereby benefiting patients. The Product is expected to have a positive impact on the Group’s financial results.Reference:1. Xu, Hong et al. Long-term Effects of Cholinesterase Inhibitors on Cognitive Decline and Mortality. Neurology vol. 96,17 (2021): e2220-e2230. doi:10.1212/WNL.00000000000118322. Safety profile of ZUNVEYL as disclosed by Alpha: https://www.alphacognition.com/investors/news/alpha-cognitions-oral-therapy-zunveyl-receives-fda-approval-to-treat-alzheimers-disease- 3. 2018 Chinese Guidelines for the Diagnosis and Treatment of Dementia and Cognitive Impairment (Chapter 1): Dementia Classification and Diagnostic Criteria [J]. National Medical Journal of China, 2018, 98 (13): 965-970. DOI: 10.3760/cma.j.issn.0376-2491.2018.13.0034. 2018 Chinese Guidelines for the Diagnosis and Treatment of Dementia and Cognitive Impairment (Chapter 2): Guidelines For Diagnosis and Treatment of Alzheimer's Disease [J]. National Medical Journal of China, 2018,98 (13): 971-977. DOI: 10.3760/cma.j.issn.0376-2491.2018.13.0045. Jia, Longfei et al. Prevalence, risk factors, and management of dementia and mild cognitive impairment in adults aged 60 years or older in China: a cross-sectional study. The Lancet. Public health vol. 5,12 (2020): e661-e671. doi:10.1016/S2468-2667(20)30185-76. Yuan, Jing et al. Severity Distribution of Alzheimer’s Disease Dementia and Mild Cognitive Impairment in the Framingham Heart Study. 1 Jan. 2021: 807-817.7. Mayo Clinic. 2024. Alzheimer’s Disease: Therapies to Improve Cognitive Symptoms and Decelerate Disease Progression. https://www.mayoclinic.org/zh-hans/diseases-conditions/alzheimers-disease/in-depth/alzheimers/art-200481038. Research Report on the Diagnosis and Treatment of Alzheimer’s Disease Patients in China (2020). Alzheimer's Disease Chinese (ADC). https://www.adc.org.cn/index.php/book/chinaadzlxzbg2020/chinaadzlxzbg2020-381.html9. Data on patient discontinuation as disclosed by Alpha: https://www.alphacognition.com/investors/news/alpha-cognitions-oral-therapy-zunveyl-receives-fda-approval-to-treat-alzheimers-disease-About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses. Among them, the skin health business has become a leading enterprise in its field, bringing economies of scale in specialty therapeutic fields. Meanwhile, CMS continuously deepens its business development in Southeast Asia and the Middle East regions, further escorting the sustainable and healthy development.CMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/Source: China Medical System Holdings Ltd. Copyright 2025 ACN Newswire via SeaPRwire.com.

- The HKTDC continues to help SMEs seize digital trade opportunities by co-hosting with the ICC DSI a masterclass on technologies such as electronic bills of lading and blockchain. More than 200 SMEs took part.- Prof Frederick Ma, Chairman of the HKTDC, emphasised that Hong Kong is actively developing its digital trade ecosystem, with a focus on innovation, efficiency and international collaboration, to consolidate its competitive advantages. As digital trade becomes more common, the HKTDC will ensure Hong Kong businesses continue to thrive and enhance the city’s role as a leading supply chain hub.- Pamela Mar, Managing Director of ICC DSI, noted that by aligning its finance, trade and logistics sectors with global digital trade standards, Hong Kong can remain competitive and resilient on the world stage and is well-positioned to spearhead Asia’s digital-trade development.- Andy Lam, Deputy Secretary for Commerce and Economic Development of the HKSAR Government, said that the Government is making reference to the Model Law on Electronic Transferable Records and is considering legislative amendments to remove the legal hurdles in the digitalisation of trade documents. The target is to submit the relevant legislative proposal to the Legislative Council next year to help industry develop technical solutions based on their actual needs.HONG KONG, July 28, 2025 - (ACN Newswire via SeaPRwire.com) - Digitalisation is reshaping the global economy, and companies must embrace digital transformation to capitalise on new opportunities. The 2025-26 Budget announced that the Hong Kong Special Administrative Region (HKSAR) Government would make reference to the Model Law on Electronic Transferable Records (MLETR) advocated by the United Nations Commission on International Trade Law (UNCITRAL) and consider legislative amendments to facilitate digitalisation of trade documents. The legislative proposal will be submitted to the Legislative Council next year. The MLETR is a global standard advocated by the UNCITRAL to provide a legal framework for electronic trade documents. Aligning local legislation with standards of the MLETR is a major endeavour in promoting trade digitalisation. In line with these efforts, the Hong Kong Trade Development Council (HKTDC) and the International Chamber of Commerce Digital Standards Initiative (ICC DSI) co-hosted the “Digital Trade Masterclass” at the Hong Kong Convention and Exhibition Centre to examine the MLETR’s potential impact on Hong Kong’s cross-border trade. Industry experts shared practical insights on digital transformation, helping equip businesses with the information they need to enhance their high value-added service capabilities. More than 200 SMEs participated in the event.As an international financial and trading centre and a leading re-export hub, Hong Kong is able to capitalise on its unique advantages to reinforce connectivity, serving as a bridge linking the mainland and global markets. It provides high-standard professional services, robust financial infrastructure and an innovative environment for international trade. The HKTDC works closely with the HKSAR Government to highlight the city’s strength in delivering high value-added services across the trade supply chain.Speaking at the event, Prof Frederick Ma, Chairman of the HKTDC, said that with the changing trade landscape, there was no better time to reinforce Hong Kong’s competitive advantages. “Hong Kong is actively developing its digital trade ecosystem, with a focus on innovation, efficiency and international collaboration, to consolidate its competitive advantages. As digital trade becomes more common, we are committed to making sure Hong Kong businesses continue to thrive. It is also a great opportunity to reinforce our city’s role as a leading supply chain hub. The HKTDC is dedicated to helping businesses leverage innovative technologies to equip businesses to be future-ready. Our Asian Logistics, Maritime and Aviation Conference (ALMAC) examines trends in global trade and supply chains, innovation and digitalisation, while our support programmes, including Transformation Sandbox, help enterprises scale up their capabilities in key areas, including digital transformation and supply chain solutions, to empower SMEs and start-ups to benefit from digital trade.”Pamela Mar, Managing Director of the ICC DSI, believes Hong Kong, as an international trade and logistics hub already aligned with global standards, will lead Asia’s future digital trade development by remaining competitive and resilient amid a shifting global landscape. “Finance, trade and logistics make up over 45 % of Hong Kong’s economy, so accelerating digitalisation in these sectors will have a positive economy-wide impact.”, said Pamela Mar. “Hong Kong is well-positioned to become a leader in this space by aligning global standards and building on its strength as a trusted hub. The adoption of MLETR is a vital step, providing legal certainty for electronic documents like bills of lading, while streamlining processes and enhancing traceability. But legal reform is only the beginning — even greater gains lie in the private sector stepping up its digital transformation, which can be enhanced by Web3 technologies.”Andy Lam, Deputy Secretary for Commerce and Economic Development of the HKSAR Government, said, “The HKSAR Government is committed to fostering an efficient business environment and maintaining the international competitiveness of Hong Kong. Facilitating the digitalisation of trade documents is part of this strategy. We anticipate that the industry would actively provide feedback and allow the Government to formulate a legal framework that is in line with the needs of the industry, on which basis the industry may propose different technical solutions. On the other hand, the Government is also pressing ahead with Phase 3 of the Trade Single Window, which will not only facilitate the industry in their submission of business-to-government trade documents such as import and export declarations, but will also connect with the Hong Kong Monetary Authority (HKMA)'s Commercial Data Interchange (CDI) to facilitate banks in accessing relevant data to process trade financing.”Industry experts discuss challenges in trade digital transformationAccelerating digital transformation across every link of the supply chain introduces unique challenges. At the Masterclass, the conference brought together specialists in digital trade finance, electronic bills of lading, digital freight and logistics, and digital retail supply chain management to share their practical experience and insights working on digital transformation.Kenise Sin, Senior Data Analyst in the Financial Infrastructure Department at the HKMA, explained: “SMEs’ access to trade finance has long been hindered by different pain points in the process. For instance, the heavy reliance on paper-based documents has led to inefficiencies and difficulties in tracking and verifying the transactions.” She added that HKMA aims to formulate a digitalisation roadmap for sea, road and air transportation cargo data by the end of this year, integrating cargo data sources across jurisdictions with the HKMA’s CDI, to enhance data sharing. In the coming two years, the HKMA will also work with the Airport Authority Hong Kong, the Transport and Logistics Bureau as well as pilot banks to leverage cargo data and CDI to improve digital trade finance.Erik Kwok, Head of Technology and Operations at Air8 — which develops a supply chain finance platform for cross-border trade — echoed these concerns: “Many small to medium-sized exporters struggle to secure funding due to inadequate data for credit assessments, hindering their ability to compete globally. These obstacles are compounded by insufficient support for risk management strategies, leaving SMEs vulnerable in a rapidly evolving market.”Another guest speaker, Candy Chan, Product Manager at IQAX, outlined how digitalising bills of lading can save both time and costs, boosting the efficiency of the entire trade ecosystem. She said many banks, freight forwarders, and customs systems still operate on fragmented digital platforms and lack interoperability. Blockchain, she argued, can bridge these silos: “Each trading partner has unique operational needs when adopting blockchain networks in digital platforms. In cross-border trade, trading and shipping documents are exchanged, and digitalised documents within a blockchain network can solve trust issues within and across networks, backed by MLETR.”Photo download: http://bit.ly/4lNB4t9Prof Frederick Ma, Chairman of the HKTDC attended the Digital Trade Masterclass and delivered the opening remarks on 28 July.(From left) Andy Lam, Deputy Secretary for Commerce and Economic Development, HKSAR Government; Prof Frederick Ma, Chairman of the HKTDC; and Pamela Mar, Managing Director, ICC DSI.Industry experts shared insights and challenges on digital transformation. Picture shows guest speakers from the Digital Trade Masterclass with the officiating guests.(From left) Kenise Sin, Senior Data Analyst, Financial Infrastructure Department, HKMA; Jack Lee, Chief Operating Officer, GS1 Hong Kong; Bertrand Chen, Chief Executive Officer, Global Shipping Business Network; Andy Lam, Deputy Secretary for Commerce and Economic Development, HKSAR Government; Prof Frederick Ma, Chairman of the HKTDC; Pamela Mar, Managing Director, ICC DSI; Ivy Tse, Co-Chief Executive Officer & Co-founder, FreightAmigo; Erik Kwok, Head of Technology and Operations, Air8; and Candy Chan, Product Manager, IQAX.Over 200 SMEs attended the Digital Trade Masterclass, reflecting strong interest.Media enquiriesPlease contact the HKTDC’s Communications & Public Affairs Department:Johnny TsuiTel: (852) 2584 4395Email: johnny.cy.tsui@hktdc.orgWinnie KanTel: (852) 2584 4055Email: winnie.wy.kan@hktdc.orgAgnes WatTel: (852) 2584 4554Email: agnes.ky.wat@hktdc.orgHKTDC Media Room: http://mediaroom.hktdc.comAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit:www.hktdc.com/aboutus. Copyright 2025 ACN Newswire via SeaPRwire.com.

SHANGHAI July 28, 2025 - (ACN Newswire via SeaPRwire.com) - 26th July 2025, CITIC Telecom International Holdings Limited (“CITIC Telecom”, SEHK:1883), Asia-Pacific leading multinational Internet-oriented telecommunications enterprise, has joined hands with its subsidiaries including Companhia de Telecomunicações de Macau, S.A.R.L. (“CTM”), CITIC Telecom CPC and China Entercom to exhibit at 2025 WAIC (World AI Conference) for four years in a row.The theme of this year's conference is “Global Solidarity in the AI Era”. In tune with the zeitgeist and guided by CITIC Group’s philosophy, “CITIC, Your Trusted Partner for Going Global and Coming to China”, CITIC Telecom focuses on the strategic direction of “AI+ Connect for Global Reach”. At the WAIC 2025, a compelling display of breakthroughs were showcased, including empowering intelligent business upgrades, enhancing connectivity in digital economies, reinforcing the dual strategies of “Going global” and “Coming to China” market flows, and integrating AI more deeply into real-world industry scenarios.CITIC Telecom continues to play a vital bridging role by actively engaging in the global technology ecosystem enabling Chinese enterprises to pursue “Going Global” strategies while accelerating international enterprises in “Coming to China”, fueling the growth of intelligent technologies.Smart CITIC: Creating Possibilities TogetherCITIC Group participated prominently in this year’s WAIC under the theme “Smart CITIC: Creating Possibilities Together”. Leveraging its integrated strengths in “Technology, Industry & Finance”, the Group showcased a wide range of innovative AI applications and industry-specific AI solutions across technological innovations, emerging industries, financial empowerment, and internationalization. As a key component and strategic pillar of CITIC’s new consumption segment, CITIC Telecom significantly contributed to the “Technology Innovation” and “Internationalization” zones. With close collaboration among its subsidiaries, the exhibit demonstrated its robust foundational tech capabilities, industrial empowerment and ecosystem synergy. It has further unlocked high-quality AI-driven growth, providing CITIC’s intelligence and smart solutions to enhance digitization in China and connect global digital economies. Additionally, a series of on-site “CITIC AI+ Practice Sharing” sessions offered valuable insights into the practical applications and commercial potential of its innovations. “AI+ Connect” for Global Reach: Powering the Next Engine of High-Quality DevelopmentAmidst rapid global digital growth, CITIC Telecom, an important cornerstone of CITIC Group’s international business, is actively embracing China’s “AI+” and high-standard opening-up strategies. It also focuses on fostering a globally interconnected digital ecosystem, deepening the two-way pathways for “Going global” and “Coming to China”, and contributing to a more open, trusted, and mutually beneficial global digital landscape.To realize this strategic vision, CITIC Telecom has established a robust global presence across five continents, comprising nearly 170 Points of Presence, 21 Cloud Service Centers, over 30 Data Centers, and three 24x7 Security Operations Centers (SOCs). These resources and infrastructure support highly responsive, global coverage, agile, digital and intelligent cloud-network-security services. Therefore, it not only provides cybersecurity protection and intelligent connectivity for both central state-owned enterprises and Chinese enterprises going global, but also delivers fast and reliable localized services to multinational corporations, positioning CITIC Telecom as a vital bridge connecting global and local markets, industries and technologies.To further its localization strategy and capability, CITIC Telecom has enhanced regional collaboration through its subsidiaries. ACCLIVIS, operating extensively across ASEAN markets, has accelerated AI, cloud security and cybersecurity deployments in critical sectors such as healthcare and manufacturing, which has infused the Southbound Corridor with sustained innovation momentum. In Greater Bay Area, CTM plays a pivotal role in the “Digital Macau” initiative targeting focus on enabling the moderate economic diversification of Macau, promote smart government, smart campus, smart transformation of various fields. Harnessing the convergence of AI and telecom technologies, it has become a powerful digital and intelligent engine driving Macau’s high-quality development.CITIC Telecom has empowered over 3,000 Chinese and international enterprises in their cross-border development, serving more than 40,000 local clients worldwide, including over 200 Fortune Global 500 enterprises. This highlights the leap from vision to execution in its global strategy, forging partnerships to shape an interconnected digital future.Harnessing Technology: Empowering the Future of “AI+ Connect”In constructing a globally interconnected digital ecosystem, CITIC Telecom is fortifying its innovation foundations to support the next-generation digital framework for enterprises. Leveraging its extensive technological expertise and innovative R&D framework, it is exploring key areas such as AI+ Big data, AI+ Networking, and AI+ Large Model applications, continuously launching scalable, deployable solutions.In the field of AI data governance, AI Databank integrates Big Data, AI, Large Language models (LLMs) and generative AI to create a unified data platform that eliminates silos and enables seamless cross-system integration. Its innovative AI data governance technology has gained widespread adoption across industries and earned the Silver Medal at the 50th International Exhibition of Inventions Geneva in 2025, highlighting CITIC Telecom's excellence in AI research and innovation.In the realm of network services, the “AI Roaming Data Acceleration Pack” project significantly enhances global data transmission efficiency and stability for multinational enterprises by optimizing routing paths and network nodes. By integrating cutting-edge intelligent technologies with the GSMA Open Gateway standards, this solution has been successfully implemented in smart tourism across Hong Kong and Macau. Its innovative approach also earned the Third Prize in the “Open Gateway Global Use Case Innovation Challenge”.In the area of smart living, CITIC Telecom featured CTM’s pioneering “Smart City” project and its 10 Gigabit network infrastructure development in Macau. Powered by a dual-engine approach combining F5G-A and 5G-A technologies, CTM has built Macau’s first “10 Gigabit All-Optical Network Smart Neighborhood”, achieving full gigabit network coverage in Macau citywide. It enables a number of intelligent applications and drives the digital transformation of public services and urban governance, as well as exemplifying a sustainable, people-centric model of urban innovation. This “Smart City” project has garnered multiple prestigious awards both domestically and internationally, underscoring its contribution to the vision of “Digital Macau” and aligning with national strategies for technological advancement.With full-lifecycle AI service capabilities, CITIC Telecom is creating a robust innovation chain — from foundational infrastructure to advanced applications — to empower industries in their digital and intelligent transformation. This drives enterprises success in the global market.AI+ Connect: Fortifying Data Security and Compliance for a Trusted Digital WorldTechnology continues to accelerate global expansion for businesses, yet it also brings rising concerns over data protection and regulatory compliance. CITIC Telecom has established a comprehensive data security and compliance system for the AI era, aligning with China’s Data Security Law and Personal Information Protection Law, as well as international regulations such as the EU’s General Data Protection Regulation (GDPR) and ASEAN's Personal Data Protection Act (PDPA). With this forward-looking approach, the company has addressed key challenges such as cross-border data transmission, data protection, and financial risk control, providing end-to-end protection to build a trusted and intelligent digital world.To empower the future with intelligence, CITIC Telecom shared multiple lightweight AI+ applications that integrate the strengths of “Technology, Industry & Finance” during the “CITIC AI+ Practice Sharing” sessions, all tailored to empowering global enterprises.“Intelligent Financial Fraud Shield”: Financial Fraud, particularly in cross-border transactions, has become a pressing concern. CITIC Telecom’s “Intelligent Financial Fraud Shield” introduces multi-layered identity verification and real-time transaction monitoring to combat fraudulent behavior in cross-border transactions, effectively safeguarding assets for financial institutions and end users. This solution demonstrates the company’s innovative leadership in the digital finance area.“AI+ Connect: Cybersecurity Redefined with Precise Analysis”: CITIC Telecom has developed an all-round, multi-layered intelligent cybersecurity framework to enhance cyber defense. To effectively prevent external threats and data breaches, its AI Pentest simulates real-world attacks and scans for vulnerabilities, enabling proactive threat detection and remediation. Supported by three self-deployed, self-managed AI-driven Security Operations Centers (SOCs), the system constructs a robust and resilient defense that integrates machine learning, big data analytics and large model technologies for real-time threat monitoring and automated response. Meanwhile, the “AI Guardrail” spans from endpoint to transmission layers, guarding against unauthorized access and cross-border data leaks.“AI+ Connect: From Technology Empowerment to Data Empowerment”: Harnessing patented innovations, CITIC Telecom applies intelligent algorithms and big data analytics to help enterprises streamline data governance, integrate cross-system resources, and automate intelligent analytical reports. These capabilities also support diverse small-scale AI applications leveraging large model technologies, from data collection and monitoring to compliance reporting. Through a unified data platform, the company is reimagining enterprise-grade data governance architecture with cutting-edge technologies.Moving forward, CITIC Telecom remains committed to “Connecting the world” and advancing the “AI+ Connect” for enterprises. By leveraging the CITIC Group’s financial, technological and industrial synergies, the company will continue to deepen its AI investments, accelerating the transformation of applicable, manageable, and reliable technologies into real-world solutions. As global cooperation in the smart era grows, CITIC Telecom strives to be a pivotal bridge connecting China and the world, facilitating high-standard opening-up strategies and supporting Chinese enterprises expand globally.Visit Our Booth at H2-A308In this era of digital intelligence, technological innovation stands as the core driver of enterprise resilience and national progress. Embracing this spirit, CITIC Telecom is fast-tracking its technological roadmap to expand its global “Tech+” presence by integrating AI, big data, cloud computing and cybersecurity. We look forward to partnering with industry peers to ignite the future of intelligence and shape a world of shared success.For more details on “CITIC AI+ Practice Sharing”, please visit: https://mp.weixin.qq.com/s/svkprkpnnoC04gdsKZh9HAAbout CITIC Telecom International Holdings Limited (HKEx: 1883)CITIC Telecom International Holdings Limited was established in 1997 in Hong Kong, and was listed on the Hong Kong Stock Exchange on 3 April 2007. As one of the largest international telecommunications hubs in Asia Pacific, CITIC Telecom provides full-scale international telecommunications services to carrier clients around the globe, and integrated enterprise services in Southeast Asia through its wholly-owned subsidiary Acclivis Technologies and Solutions Pte. Ltd.CITIC Telecom International CPC Limited (“CPC”), CITIC Telecom’s wholly-owned subsidiary, provides end-to-end information and communications technology solutions to multinational corporate clients and business clients. CPC is one of the most trusted partners of these clients in the Asia-Pacific region, and provides a full range of ICT services to major enterprises and multinational corporate clients in Chinese mainland through its subsidiary China Enterprise ICT Solutions Limited.CITIC Telecom holds 99% equity interest in Companhia de Telecomunicações de Macau, S.A.R.L. (“CTM”). CTM is one of the leading integrated telecommunications services providers in Macau, and is the only full telecommunications services and ICT services provider in Macau. With a leading position in the market, CTM plays an important role in the ongoing development of Macau. CITIC Telecom has established branch organisations in 22 countries and regions, with approximately 2,500 staff and nearly 170 PoPs, and business serving 160 countries and regions, connecting to over 600 operators globally, and serving around 3,000 multinational corporations and 40,000 local companies around the globe.CITIC Group Corporation, a large multinational conglomerate headquartered in the People’s Republic of China, is the ultimate holding company of CITIC Telecom.For more information, please visit: www.citictel.comMedia Enquiry:CITIC TelecomMs. Sylvia LiTel: +852 3423 3168Email: sylviali@citictel.comCatherine YuenCITIC Telecom CPC (852) 2170 7536Email: catherine.yuen@citictel-cpc.com Copyright 2025 ACN Newswire via SeaPRwire.com.

香港，2025年7月28日 - (亞太商訊 via SeaPRwire.com) - 品創控股有限公司（「品創控股」或「公司」，連同其附屬公司統稱為「集團」；股份代號：8066）公佈向集團兩家全資附屬公司山西動創數娛科技集團有限公司（「山西動創」）及賽博幻境（香港）有限公司（「賽博幻境」）的10名合資格僱員（「承授人」）授出購股權，以獎勵僱員在推動集團業務持續增長及實現卓越業績的重大貢獻。同時，透過授予購股權，能進一步將僱員的利益與集團的長遠發展目標緊密結合，激勵僱員積極參與集團的未來發展，提升整體競爭力及經營表現，並鞏固僱員長期為集團服務的承諾及意願。購股權計劃合共授出52,500,000份購股權，每份購股權賦予承授人權利認購一股股份，行使期為授出日起計十年。值得一提的是，是次授出之購股權的行使條件與山西動創及賽博幻境的業績掛鈎，兩家公司截至2025年9月30日止九個月的未經審核稅前溢利總額需不少於7,500萬港元，此舉反映集團對兩家附屬公司未來表現及業績達標的高度信心。關於品創控股有限公司品創控股有限公司的使命是妥善運用公司所獲得的資本與獨特投資機會，為股東提供穩定的優渥收入與獲利。品創由三個主要事業部門組成，包括智能卡製造服務、投資服務與資源回收投資，主要業務為生產及銷售智能卡、提供定製智能卡應用系統、提供財務及管理諮詢服務、廢舊金屬銷售及貿易、以及媒體與娛樂行業之投資。公司的總部位於香港，旗下控股公司與投資則遍佈大中華地區。關於山西動創數娛科技集團有限公司山西動創數娛科技集團有限公司（前稱「海南動創數娛科技集團有限公司」）從事運營泛娛樂數字生態系統會員電子商務平台，平台主要提供帶私域流量的娛樂電子商務，包括提供數字產品及服務。關於賽博幻境（香港）有限公司賽博幻境（香港）有限公司（前稱「智能生產管理系統有限公司」）從事提供人工智能語音服務。 Copyright 2025 亞太商訊 via SeaPRwire.com.

HONG KONG, July 28, 2025 - (ACN Newswire via SeaPRwire.com) - Phoenitron Holdings Limited (“Phoenitron” or the “Company”, together with its subsidiaries, the “Group”; stock code: 8066) announced the grant of share options to 10 eligible employees (the “Grantees”) of its two wholly-owned subsidiaries, namely Shanxi Dongchuang Digital Entertainment Technology Group Company Limited (“Shanxi Dongchuang”) and CyberMirage (HK) Limited (“CyberMirage”). This initiative recognizes the significant contributions these employees have made in driving the Group’s sustained growth and exceptional performance. The grant of share options also further aligns employees’ interests with the Group’s long-term development goals, motivates them to actively participate in the Group's future growth, enhances overall competitiveness and operational performance, and strengthens their commitment and willingness to serve the Group in the long term.An aggregate of 52,500,000 share options were granted under the share option scheme, and each option entitles the grantee to subscribe for one share. The option exercise period is 10 years commencing from the date of grant. Worthy of notice is the exercise conditions for the share options granted are linked to the performance of Shanxi Dongchuang and CyberMirage. The unaudited aggregate profits before tax of the two companies for the nine months ending 30 September 2025 have to be not less than HK$75 million, reflecting the Group’s strong confidence in the future performance and ability to meet performance targets of the two subsidiaries.About Phoenitron Holdings LimitedThe mission of Phoenitron Holdings Limited is to provide shareholders with an optimum steam of steady income and gains by best leveraging the Company’s access to capital and unique investment opportunities. Phoenitron is comprised of three primary business segments, including smartcard manufacturing services, financial consulting and recycled resources investment. Its principal activities are manufacturing and sale of smart cards, provision of customised smart card application systems, provision of financial and management consultancy services, sale and trading of scrap metals and investment in the media and entertainment industry. Headquartered in Hong Kong, the Company has primary holdings and investment across Greater China. About Shanxi Dongchuang Digital Entertainment Technology Group Company LimitedShanxi Dongchuang Digital Entertainment Technology Group Company Limited (formerly known as “Hainan Dongchuang Digital Entertainment Technology Group Company Limited”) operates a pan-entertainment digital ecosystem membership e-commerce platform, which primarily provides entertainment e-commerce with private domain traffic, including the provision of digital products and services.About CyberMirage (HK) LimitedCyberMirage (HK) Limited (formerly known as "PMIS Limited") provides artificial intelligence voice services. Copyright 2025 ACN Newswire via SeaPRwire.com.

RIYADH, KSA, July 27, 2025 - (ACN Newswire via SeaPRwire.com) - The Saudi Electricity Company (SEC) has achieved a significant milestone in its Environmental, Social, and Governance (ESG) performance, as evaluated by S&P Global. The company scored 65 out of 100, marking a 30% increase compared to its 2024 score, and an 85% improvement over its 2023 rating. This accomplishment highlights SEC's strategic progress and reinforces its position as a regional leader and a benchmark for sustainable excellence in the energy sector. Notably, SEC's score exceeds the global utilities sector average of 39 points by 66%, demonstrating its strong commitment to sustainable development. The rating reflects SEC's comprehensive institutional commitment to sustainability, driven by effective governance frameworks, ambitious strategies, and tangible improvements in environmental and social performance. SEC also showcased proactive disclosure aligned with leading international sustainability reporting standards. This progress further underscores SEC's alignment with Saudi Vision 2030, particularly in advancing sustainable energy, enhancing transparency, strengthening investor confidence, and adopting global ESG best practices. SEC reaffirmed its commitment to continuously improving its ESG performance by deeply embedding sustainability across all operations, positioning itself as a trusted and responsible energy provider both regionally and globally.Contact InformationSaudi Electricity Company (SEC)Media Relations Departmentalkahrabacare@se.com.saUnified Call Center: 920000222 Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, July 26, 2025 - (ACN Newswire via SeaPRwire.com) - As one of the leading stock brokerage account opening offers comparison and practical investment education media platform in Hong Kong and Asia, Theinvestmedia.com ( https://theinvestmedia.com ) today proudly announced the exclusive update and launch of its fully optimized "Brokerage Account Opening Offers" special section on its website. It's also releasing a series of "Brokerage Account Opening and Platform Usage Practical Tutorials" personally written by its senior expert team. This initiative aims to empower a wide range of individual investors, especially those seeking the best brokerage account opening offers and practical platform usage tutorials, by providing timely, specific, and highly reliable information, ensuring they can make the smartest and most efficient decisions in the ever-changing global financial markets.Theinvestmedia.com's core team comprises seasoned investment bankers, securities firm management, and Certified Public Accountants (CPAs), boasting over eight years of hands-on financial investment experience. The team deeply understands the critical impact of financial information's professionalism and timeliness on investment decisions. This in-depth update focusing on brokerage account opening tutorials and exclusive offers is a testament to the team's commitment to transforming rich experience into tangible user value.Exclusive Brokerage Account Opening Offers: Real-World Testing and In-Depth Tutorial AnalysisIn response to the market's strong interest in brokerage account opening offers, Theinvestmedia.com not only provides a detailed list of all publicly available offers but also exclusively reveals account opening promotions launched in collaboration with various licensed financial brokerage partners (for details, please refer to Theinvestmedia.com's official website). These offers are not only highly attractive, but the team also provides an in-depth analysis in the tutorials, covering the application process, terms and conditions, and how to maximize the value of these account opening offers. This aims to help users clearly understand the benefits and avoid any potential confusion. The team's goal is to ensure users receive the most transparent and comprehensive information when choosing to open accounts with top-tier brokers (e.g., IBKR account opening offers, Futu, Tiger, OSL, etc.).Practical Guides: From Illustrated Brokerage Account Opening Procedures to Advanced Platform Usage Tutorials and StrategiesBeyond the brokerage account opening offers comparison, another major highlight of this update is a series of brokerage account opening and platform usage practical tutorials, thoroughly tested and verified by the team. These in-depth tutorials cover:Most Detailed Illustrated Account Opening Procedures and Techniques: Providing illustrated steps and tips for common account opening queries and operational challenges (e.g., illustrated IBKR account opening procedures).In-Depth Navigation of Different Securities Platform Functions: Introducing the trading interfaces and frequently used features for diverse investment products (e.g., US stocks, Hong Kong stocks, Japanese stocks, forex, bonds, ETFs, etc.) available on these platforms.Foreign Exchange Rate Comparisons : Offering practical advice on foreign exchange rate comparisons for USD to HKD, Yen to HKD, GBP to HKD, EUR to HKD, CAD to HKD, AUD to HKD, RMB to HKD, SGD to HKD, and other foreign currencies, as well as guidance on deposits and withdrawals in various currencies.Specific Trading Tools and Strategy Application: Sharing how the senior team leverages brokerage platforms for effective risk management and strategy execution for wealth management purpose.Every guide undergoes meticulous data collection from multiple sources, citing only authoritative data from official reports of licensed brokers and multiple account opening tests. Before publication, all content undergoes rigorous multi-team internal verification and professional review by senior compliance advisors, ensuring the authority and 100% accuracy of the information.Building Trust with a Customer-Centric Approach: User Feedback and Customer Service SupportTheinvestmedia.com is committed to being user-centric, with its trustworthiness built on transparency and prompt responsiveness. The platform has a growing number of email subscribers, whose active engagement and positive feedback widely confirm the practical value of the website's content. Theinvestmedia.com also maintains a professional customer service team, accessible via the website or email (hello@theinvestmedia.com), providing personalized assistance. This ensures that users with any questions regarding brokerage account opening offers, platform usage guides, or other tutorial-related information can receive immediate and professional support during business hours.The platform's founding team stated: "We firmly believe that truly valuable financial information must be practical, timely, and verifiable. This exclusive update on brokerage account opening offers and practical tutorials is our latest achievement in upholding this philosophy. We don't just provide 'fish'; we strive to teach 'fishing,' empowering every investor to confidently navigate the global financial markets."Theinvestmedia.com sincerely invites all readers interested in brokerage account opening offers, securities platform operations, and professional investment knowledge to visit Theinvestmedia.com immediately. Explore these exclusive resources, forged from the experience of financial experts, and embark on your journey of confident investment learning.About Theinvestmedia.comTheinvestmedia.com is an online media platform dedicated to providing individual investors with brokerage account opening offer comparisons and professional investment education. It is operated by an expert team with over eight years of hands-on financial investment experience. The website's content covers diverse investment topics, including US stocks, Hong Kong stocks, Japanese stocks, forex, bonds, and ETFs, with a particular focus on account opening offer comparisons, account opening tutorials, and stock account operations (e.g., IB account opening offers), offering in-depth analysis and explanations. Theinvestmedia.com aims to simplify complex financial concepts, helping investors build a solid foundation of investment knowledge and make informed financial decisions. All content is for actual experience sharing and public educational purposes; the platform does not provide any investment advice.Media & Reader Inquiries:Theinvestmedia.com Public Relations DepartmentEmail: hello@theinvestmedia.comWebsite: https://theinvestmedia.comFacebook: https://www.facebook.com/theinvestmediaX.com: https://x.com/theinvestmediaSOURCE: Theinvestmedia Copyright 2025 ACN Newswire via SeaPRwire.com.

香港，2025年7月25日 - (亞太商訊 via SeaPRwire.com) - 下一代肿瘤免疫疗法的领跑者 - 南京維立志博生物科技股份有限公司(「維立志博」或「公司」，股份代號：9887.HK)，宣佈於香港聯合交易所有限公司（「香港聯交所」）主板上市，股票代號爲9887.HK。維立志博此次發售每手買賣單位100股H股，最終發行價為每股35.00港元，處於31.60港元至35.00港元價格區間的上限。基礎發行股數為36,862,500股H股（經計及發售量調整權獲悉數行使及視乎超額配股權行使與否而定），其中香港發售股份數目為16,027,200股H股（經重新分配後予以調整），國際發售股份數目為20,835,300股H股（經計及發售量調整權獲悉數行使、經重新分配後予以調整及視乎超額配股權行使與否而定）。超額配售權方面，超額分配的發售股份數目（經計及發售量調整權獲悉數行使）為12,821,700股H股，均來自國際發售。募集資金規模方面，算上綠鞋後總發行規模可達1.89億美元。融资达1.89億港元 18A最强基石阵容领跑維立志博此次IPO招股引入基石投资者9席，合共認購約5.42億港元。基石投资者名单集结多家头部医疗专业基金及长线机构，既有國際知名醫療專業基金OrbiMed、TruMed,也包含國內頭部公募基金易方达基金；既包括活躍香港二級市場的創新藥投資基金Foresight Funds、Sage Partners，更不乏腾讯、高毅等長線價值的國內頭部著名私募基金。此外，還有老股東著名醫藥專業投資基金正心谷资本和汉康资本的加倉。摩根士丹利、中信证券為本次發行之聯席保薦人。根據公司策略，維立志博本次IPO募集所得資金淨額的約65.0%擬將用於臨床階段候選藥物正在進行及計畫進行的臨床開發和監管事務；約15.0%將用於推進臨床前資產、擴展現有管線並優化技術平台；約10.0%將主要用於提升生產能力，其次用於候選藥物獲批銷售後的商業化；以及約10.0%將用於營運資金及一般企業用途。公司於2012年成立，是一家臨床階段生物科技公司，專注於腫瘤、自身免疫性疾病及其他重大疾病新療法的發現、開發及商業化。公司已建立多元化的產品組合，包括4款核心及主要產品，各款產品組合均處於全球臨床進度領先的候選藥物之列（不論於其各自藥物類別或針對相同靶點的藥物當中）。其中，核心產品LBL-024由公司內部開發，是一款處於註冊臨床階段的PD-L1與4-1BB雙特異性抗體，其為全球首個已處於註冊臨床階段的靶向4-1BB受體的療法，亦有望成為治療晚期肺外神經內分泌癌的首款獲批藥物。維立志博的核心業務模式是自主發現、開發及商業化腫瘤免疫療法。公司通過重點佈局腫瘤免疫2.0（IO 2.0）、T細胞銜接器（TCE）和抗體偶聯藥物（ADC）三大領域，積極探索多領域組合療法，在全球腫瘤治療領域建立了差異化競爭優勢。截至目前，維立志博的腫瘤管線共12款產品，分別為3款單克隆抗體、5款雙特異性抗體、3款抗體偶聯藥物(ADC)以及1款雙特異性融合蛋白。此外，維立志博還佈局針2款自身免疫性疾病，包括1款雙特異性融合蛋白及1款三特異性抗體。技術平台持續創新維基 多款核心產品顯露行業頭部潛質公司採用科學驅動的研發方法，開發了包括LeadsBody™平台（CD3 T-cell engager平台）、X-body™平台（4-1BB engager平台）、Linker-payload(ADC技術平台)在內的專有技術平台。技術平台是公司持續創新的基石，並已通過雙特異性抗體組合的臨床結果得到驗證。LeadsBody™平台為靶向CD3的雙特異性抗體的開發提供了堅實的技術支援，通過對TCE分子設計進行多樣化修改，可精細調節TCE對CD3及腫瘤相關抗原的親和力，通過精准的空間位阻分子結構設計，做到只在腫瘤微環境中條件啟動，從而有效減少細胞因數風暴風險，降低系統性毒性。通過LeadsBody™平台量身定制的分子定位及空間排列能優化療效與安全性之間的平衡，減少與毒性相關的治療中斷，延長治療持續時間，提高患者的生活品質。基於這一平台，維立志博已在更具市場前景的實體瘤治療領域建立了先發優勢，截至目前，已佈局6款差異化TCE管線產品，成功建起覆蓋血液瘤、實體瘤及自免三大疾病領域的TCE產品矩陣。血液瘤領域- LBL-034：GPRC5D/CD3雙特異性抗體，用於治療多發性骨髓瘤。- LBL-043：LILRB4/CD3雙特異性抗體，用於治療急性髓系白血病及多發性骨髓瘤。實體瘤領域- LBL-033：MUC16/CD3雙特異性抗體，用於治療MUC16高表達的實體瘤，特別是卵巢癌、宮頸癌及子宮內膜癌等婦科癌症。- LBL-054：CDH17/CD3 T-cell engager，在結直腸癌、胃癌、胰腺導管腺癌、神經內分泌癌等廣泛適應症中有良好應用前景。- LBL-058：靶向DLL3的TCE雙特異性抗體-藥物偶聯物，全球首創的TCE ADC新品類產品，在DLL3表達陽性的小細胞肺癌、神經內分泌腫瘤治療中具有良好前景。自免領域- LBL-051：全球首創CD19/BCMA/CD3三特異性抗體，可有效阻斷B細胞及漿細胞產生自體抗體，同時有可能持續抑制B細胞過度啟動、分化及轉化為漿細胞，從而有望透過調節B細胞調節的多個方面實現卓越的治療效果。目前已與知名生物技術風險投資公司Aditum Bio成立的NewCo達成合作。X-body™平台利用先進的抗體工程技術，以2:2結構創造差異化的雙特異性抗體，其首個產品LBL-024開創性地採用PD-L1/4-1BB雙特異性抗體設計，獨特的分子設計使LBL-024能夠做到在腫瘤微環境中條件啟動4-1BB的激動劑作用，克服有關4-1BB系統性毒性尤其是肝毒性這一主要障礙，降低全身毒性的風險，成功攻克了4-1BB這個腫瘤免疫明星靶點開發的行業難題，成為全球首個也是唯一一款進入註冊臨床階段的4-1BB抗體藥。 值得特別指出的是，4-1BB作為激動劑，能夠重新啟動衰竭的T細胞並大量擴增，因此特別適合治療PD-1/PD-L1耐藥的或無效的所謂冷腫瘤。公司目標為發展成為一家綜合性生物技術公司，迄今為止，公司已經建立從早期篩選及發現、臨床前研究、臨床開發、CMC到中試生產的整個藥物開發過程中的所有基本功能。該等綜合能力凸顯公司在藥物開發活動的可擴展性及可複製性，使其能夠持續推進候選藥物的開發。利用該等各不相同但相互關聯的功能之間的協同作用，在短短三年內即實現從靶點選擇至提交IND的高效藥物開發流程，根據弗若斯特沙利文的資料，此優於行業約5至6年的平均水平。作為自主開發的補充，維立志博亦與第三方合作進行候選藥物的臨床開發及商業化，以通過對外授權許可、商業化合作或其他戰略合作更好地把握市場機遇。隨著臨床資產接近商業化上市，公司可能會考慮建立具商業規模的生產設施，並透過合作及內部銷售團隊加強商業化能力。南京維立志博生物科技股份有限公司(「維立志博」或「公司」；股份代號：9887.HK)是一家臨床階段的生物科技公司，公司成立於2012年，致力於創新療法的發現、開發及商業化，以滿足中國及全球在腫瘤、自身免疫性疾病及其他重大疾病方面未獲滿足的醫療需求。公司作為下一代腫瘤免疫療法的領跑者，擁有涵蓋14款創新候選藥物的差異化創新管線，其中6款已成功進入臨床階段，4款主要產品均處於全球臨床進度領先的候選藥物之列。公司採用科學驅動的研發方法，已成功建立涵蓋抗體發現及工程、體內及體外療效評估以及成藥性評估的綜合研發能力。公司亦開發了包括LeadsBody™平台（CD3 T-cell engager平台）、X-body™平台（4-1BB engager平台）在內的專有技術平台。技術平台是公司持續創新的基石，並已通過雙特異性抗體組合的臨床結果得到驗證。公司成功建立起了在早期研發、轉化醫學、臨床開發、CMC以及業務拓展方面無縫銜接的自主能力。公司候選藥物的創新性質及競爭優勢，配合其全球視野、積極主動的策略及高效的臨床驗證使公司成為備受歡迎的合作夥伴。此新聞稿由博達浩華國際財經傳訊集團代表南京維立志博生物科技股份有限公司發佈。如有垂詢，請聯絡︰博達浩華國際財經傳訊集團馮嘉莉女士(852)31506763kelly.fung@h-advisors.global王佩女士(86)13520068960evie.wang@h-advisors.global Copyright 2025 亞太商訊 via SeaPRwire.com.

香港, 2025年7月26日 - (亞太商訊 via SeaPRwire.com) - 作為香港及亞洲其中一個領先的股票開戶優惠比較及實戰投資教學媒體平台，https://theinvestmedia.com 今日隆重宣布，其網站已獨家更新並推出全面優化的「券商開戶優惠」專題頁面，同時發佈一系列由資深專家團隊親身撰寫的「券商開戶及平台使用實戰教學」。此舉旨在透過即時、具體且高度可信賴的資訊，賦能廣大個人投資者，特別是那些尋求券商開戶優惠最佳方案及平台實用操作教學的用戶，確保其在瞬息萬變的全球金融市場中，能夠做出最明智、最有效率的決策。Theinvestmedia.com 核心團隊由超過八年金融投資實戰經驗的資深投資銀行家、證券商管理層及註冊會計師 (CPA) 組成。團隊深知金融資訊的專業性與即時性對於投資決策的關鍵影響。本次針對券商開戶教學與獨家開戶優惠的深度更新，正是團隊將豐富經驗轉化為實際用戶價值的體現。獨家券商開戶優惠，實測與深度教學解析為回應市場對券商開戶優惠的高度關注，Theinvestmedia.com 不僅詳細羅列了當前市場上所有公開的開戶優惠，更獨家公開與不同持牌金融券商合作夥伴聯手推出的開戶優惠（詳情請參閱 Theinvestmedia.com 官方網頁）。這些開戶優惠不僅極具吸引力，團隊更在教學指南中深度解析其申領流程、條款細則及如何獲得最多開戶優惠價值，旨在幫助用戶清晰掌握，避免任何潛在困惑。團隊的目標是讓用戶在選擇不同頂級券商開戶時 (例如 IB開戶優惠、富途、老虎、OSL等)，能獲得最透明、最全面的開戶優惠資訊。實戰指南：從圖解券商開戶流程到進階平台使用教學及策略除了開戶優惠優惠比較，本次更新的另一大亮點是一系列經團隊實測與驗證的券商開戶及平台使用實戰教學。這些教學指南深入淺出地涵蓋：圖解最詳細的開戶流程及技巧： 針對常見開戶疑問與操作難點，提供圖解步驟與提示 (例如圖解IB開戶)。不同證券平台功能深度導覽： 介紹其多元投資產品（例如美股、港股、日股、外匯、債券、ETF 等）的交易介面介紹與常用功能。 外幣兌換匯率比較： 針對美元兑港元、日元兑港元、英鎊兑港元、歐元兑港元、加元兑港元、澳元兑港元、人民幣兑港元、新加坡幣兑港元及其他外幣的兌換匯率比較、還有不同貨幣的出金、入金的實用建議。特定交易工具與策略應用： 分享資深團隊在實際操作中如何利用券商平台進行有效的風險管理與策略執行。每一篇指南都經過多源頭詳盡資料收集，並只引用持牌券商官方報告及多次開戶測試等權威數據來源。在發佈前，所有內容皆會歷經嚴格的多重團隊內部核實及資深合規顧問的專業審閱，確保資訊的權威性與百分百準確性。以客為本建立信任：用戶回饋與客戶服務支援Theinvestmedia.com 堅持以用戶為中心，平台的信任度建立在透明與快速回應之上。平台已有多名電子郵件訂閱用戶並持續增長，其積極的互動與回饋廣受用戶好評，證明了網站內容的實際價值。Theinvestmedia.com更設有專業客戶服務團隊，可透過網站或電郵（hello@theinvestmedia.com）為用戶提供個人化的疑難解答，確保用戶如對券商開戶優惠、平台使用攻略或任何教學相關資訊有任何疑問，都能在辦公時間內獲得即時、專業的支援。平台創始團隊表示：「我們深信，真正有價值的金融資訊必須是實用、即時且可驗證的。這次針對券商開戶的獨家開戶優惠與實戰教學指南，正是我們踐行這一理念的最新成果。我們不僅提供『魚』，更致力於教導『漁』，賦能每位投資者自信地駕馭全球金融市場。」Theinvestmedia.com 誠摯邀請所有對券商開戶優惠、證券平台操作及專業投資知識感興趣的讀者，立即瀏覽 Theinvestmedia.com，探索這些由金融專家經驗淬鍊而成的獨家資源，開啟您的穩健投資學習之路。關於 Theinvestmedia.comTheinvestmedia.com 是一個專注於為個人投資者提供開戶優惠比較及專業投資教學資訊的線上媒體平台，由一支具備逾八年金融實戰經驗的專家團隊營運。網站內容涵蓋美股、港股、日股、外匯、債券、ETF 等多元投資主題，並特別針對開戶優惠比較、開戶教學及股票戶口操作 (例如IB開戶優惠) 提供深入教學及解析。Theinvestmedia.com 致力於簡化複雜的金融概念，幫助投資者建立堅實的投資知識基礎，做出明智的理財決定。所有內容均為實際經驗分享及向公眾作為教學用途，平台不會提供任何投資建議。傳媒及讀者查詢：Theinvestmedia.com 公關部電子郵件: hello@theinvestmedia.com網址: https://theinvestmedia.comFacebook: https://www.facebook.com/theinvestmediaX.com: https://x.com/theinvestmediaSOURCE: Theinvestmedia Copyright 2025 亞太商訊 via SeaPRwire.com.

香港，2025年7月25日 - (亞太商訊 via SeaPRwire.com) - 億勝生物科技有限公司（「億勝生物」或「集團」，股票代碼：1061.HK）欣然宣布，集團間接全資附屬公司珠海億勝生物製藥有限公司已收到國家藥品監督管理局批准於中華人民共和國進行多劑量地誇磷索鈉滴眼液（「獲批准産品」）注册及商業化。獲批准産品是一款含有3%地誇磷索鈉（5ml:150mg）的多劑量滴眼液劑型，適用於包括結膜上皮損傷和泪液异常在內的乾眼症的治療。該活性藥物成分地誇磷索鈉是一種P2Y2受體激動劑，它作用於結膜組織，促進含有水分和分泌性粘蛋白的泪液分泌。它還可促進角膜上皮上膜結合型粘蛋白的表達。通過提升泪液中的脂質含量，它從數量和質量上改善泪液异常，並顯示出使眼表狀况接近正常、改善乾眼症狀和角膜上皮損傷的療效。獲批准産品將與集團已獲批的不含防腐劑單劑量地誇磷索鈉滴眼液一並，為不同類型的中國患者提供更多優質治療選擇。此地誇磷索鈉滴眼液的成功獲批將進一步豐富集團眼科産品組合，增强集團在眼科領域的市場地位。關於億勝生物（股票代碼﹕1061.HK）億勝生物是一間專注於研發、生産和銷售基因工程藥物b-bFGF的生物製藥企業，擁有包括貝複舒®、貝複濟®、貝複新®在內的六種基因工程藥物在中國上市銷售。此外，公司還擁有包含一系列不含防腐劑單劑量滴眼液和適麗順®卵磷脂絡合碘膠囊等的多元化産品組合，主要應用於眼科及皮膚科處方藥領域的創傷修復及疾病治療。這些産品在公司於中國的44個區域辦事處的支持下，在逾14,000家醫院進行營銷和銷售。依托自身在生長因子和抗體技術領域的研發平台，億勝生物在多個臨床階段擁有强大的項目管綫，涵蓋廣泛的領域和適應症。 Copyright 2025 亞太商訊 via SeaPRwire.com.

上海，2025年7月25日 - (亞太商訊 via SeaPRwire.com) - 雲頂新耀有限公司（HKEX1952.HK）是一家專注於創新藥研發、臨床開發、制造和商業化的生物制藥公司，今日宣布以先舊後新配售22,561,000股，集資約15.725億港元，發行股份數占現有股本約6.87%, 占經擴大後的總股數約6.43%。雲頂新耀、賣方（控股股東康橋資本）與配售代理簽訂先舊後新方式的配股協議，配售22,561,000股份，每股配售價69.70港元，較於最後交易日（即配售及認購協議日期前一天）在聯交所報所報收市價每股77.55港元折讓約10.12%，亦較於緊接最後交易日（包括該日）前連續五個交易日在聯交所所報平均收市價每股73.35港元折讓約4.98%，較於緊接最後交易日（包括該日）前連續三十個交易日在聯交所所報成交量加權平均價每股60.01港元溢價16.15 %。所得款項總額預期約為15.725億港元，而所得款項淨額（經扣除所有相關成本及開支，包括傭金及征費）將約為15.534億港元。雲頂新耀預計配售所得款項，其中50 %（約7.767億港元）用於開發自主全球研發平台及新產品管線；另外40 %（約6.214億港元）用於推進新產品商業化，包括推出新產品；及10 %（約1.553億港元）用作營業資金以及一般及行政用途。雲頂新耀首席執行官羅永慶表示，「此次配售受到多家國際長線持有基金青睞，獲得數倍超額認購，反映了資本市場對雲頂新耀商業化能力與創新研發實力的高度認可，也體現出投資者對公司長期發展戰略的充分信心。我們將充分利用此次融資所得，加快創新藥物和AI+mRNA平台的開發，同時推進現有產品的商業化進程。憑借更為充足的資本基礎，我們有信心在商業化拓展與研發創新雙線並進，不斷為患者與投資者創造更大價值。」公司已構建國際領先的、完全整合且本地化的AI+mRNA平台，重點推進腫瘤和自身免疫疾病領域的產品管線開發，包括通用型現貨腫瘤治療性疫苗EVM14、個體化腫瘤治療性疫苗EVM16，以及自體生成CAR-T項目。- 雲頂新耀自主研發的首款個性化mRNA治療性腫瘤疫苗EVM16 的IIT研究已在今年3月於北京大學腫瘤醫院順利完成首例患者給藥。該臨床試驗初步數據顯示，即使低起始劑量也能激發晚期腫瘤患者特異性T細胞反應，具有良好的免疫原性。- 通用型現貨腫瘤治療性疫苗EVM14注射液的新藥臨床試驗申請（IND）已獲中國國家藥品監督管理局和美國食品藥品監督管理局（FDA）受理，成為公司首個實現「中美雙報」的mRNA腫瘤治療性疫苗。雲頂新耀嘉善工廠已於2025年6月9日順利放行首批GMP臨床試驗樣品，該批樣品將用於支持雲頂新耀在中美兩地開展EVM14的臨床試驗。- 自體生成CAR-T項目也已在人源化小鼠與非人靈長類（猴）模型中驗證有效，具備現貨型、無需淋巴耗竭、劑量可控等優勢，展現了開發用於腫瘤及自身免疫疾病的潛力。擁有全球權益的新一代共價可逆BTK抑制劑EVER001正開展全球多中心臨床研究，主要用於治療原發性膜性腎病（pMN）等多種原發性腎小球疾病。其在原發性膜性腎病1b/2a期研究中展現出起效快、緩解持續、耐受性好、口服便捷等綜合優勢，有望為全球患者帶來更優治療選擇。耐賦康®作為首個且唯一在中國、美國和歐洲獲得完全批准的IgA腎病對因治療藥物，自納入中國國家醫保目錄以來快速放量，已惠及超過兩萬名患者。公司亦正加快推進Gd-IgA1診斷試劑的轉化，致力打造覆蓋診斷、治療、長期管理的一體化IgA腎病疾病管理生態。伊曲莫德（維適平®）在中國大陸的新藥上市申請也已獲受理，預計2025年底至2026年初獲批，其新藥上市申請也已獲韓國受理。伊曲莫德已相繼在中國澳門，新加坡和中國香港獲批，並被納入粵港澳大灣區內地9市臨床急需進口港澳藥品醫療器械目錄（2024年），已在大灣區先行使用惠及潰瘍性結腸炎患者，成為雲頂新耀第三款商業化新藥。2025年3月，雲頂新耀啟動了伊曲莫德位於嘉善工廠的生產建設項目，為伊曲莫德的本地化生產提供支持。雲頂新耀正加快推進多個核心管線及技術平台的戰略布局，進一步鞏固其在亞洲領先創新藥企中的市場地位。關於雲頂新耀雲頂新耀是一家專注於創新藥和疫苗研發、臨床開發、制造和商業化的生物制藥公司，致力於滿足亞洲市場尚未滿足的醫療需求。雲頂新耀的管理團隊在中國及全球領先制藥企業從事過高質量研發、臨床開發、藥政事務、化學制造與控制（CMC）、業務發展和商業化運營，擁有深厚的專長和豐富的經驗。雲頂新耀已打造多款疾病首創或者同類最佳的藥物組合，公司的治療領域包括腎科疾病、感染性和傳染性疾病、自身免疫性疾病。有關更多信息，請訪問公司網站：www.everestmedicines.com。前瞻性聲明本新聞稿所發布的信息中可能會包含某些前瞻性表述，乃基於本公司或管理層在做出表述時對公司業務運營情況及財務狀況的現有看法、相信、和現有預期，可能會使用"將"、"預期"、"預測"、"期望"、"打算"、"計劃"、"相信"、"預估"、"確信"及其他類似詞語進行表述。這些前瞻性表述並非對未來業績的保證，會受到風險、不確定性及其他因素的影響，有些乃超出本公司的控制範圍，難以預計。因此，受我們的業務、競爭環境、政治、經濟、法律和社會情況的未來變化及發展等各種因素及假設的影響，實際結果可能會與前瞻性表述所含資料有較大差別。本公司及各附屬公司、各位董事、管理人員、顧問及代理未曾且概不承擔更新該稿件所載前瞻性表述以反映在本新聞稿發布日後最新信息、未來項目或情形的任何義務，除非法律要求。 Copyright 2025 亞太商訊 via SeaPRwire.com.

香港，2025年7月25日 - (亞太商訊 via SeaPRwire.com) - 隨著粵港澳大灣區建設不斷深化，區域內居民對跨境醫療服務與醫療保險協同發展的需求日益迫切。7月24日，一場以"粵港澳大灣區醫療保險發展"為主題的行業論壇於香港舉行，來自保險、醫療、科技等領域的機構代表與專家齊聚一堂，圍繞跨境醫療保障一體化、保險產品創新與服務標準化等核心議題展開深入交流。論壇期間，各方共同探討大灣區醫療保險發展新路徑，並見證跨境醫療行業解決方案正式發佈。聚焦醫療互聯互通，發佈跨境保障方案論壇上，鎂信健康創始人兼首席執行官張小棟先生指出，粵港澳大灣區作為我國經濟最具活力的區域之一，在國家發展大局中具有重要戰略地位。"塑造健康灣區"戰略的踐行，是對千萬灣區居民"病有所醫、醫有所保"期盼的回應。鎂信健康圍繞"藥品可及、醫療連接、支付簡化"三個核心痛點，推出跨境醫療解決方案，具體涵蓋：第一件事，是"把藥帶進來"。依託鎂信創新藥械的資源優勢，致力於把最新上市的癌症、罕見病治療藥、以及海南特藥特械等全球創新藥械帶到大灣區患者的身邊；第二件事，是"把醫連起來"。提供包括專家預約、陪診、第二診療意見、住院手術安排等全流程服務，優化港人北上診療體驗；第三件事，是"把支付變簡單"。依託鎂信的一碼直付平臺，探索實現患者北上就醫無需墊付，努力讓跨境醫療的保險理賠像掃碼一樣簡單。鎂信健康創始人兼首席執行官 張小棟在跨境醫療解決方案環節，中再壽險產品開發部總經理王明彥先生與鎂信健康首席商務官郎立良先生也分別發表主題演講。他們深入探討了跨境醫療在大灣區面臨的機遇與挑戰，分享了在產品設計、服務模式等方面的創新實踐與經驗。匯聚行業智慧 共建健康灣區活動現場同步舉行「服務國家戰略，共建健康灣區」發佈儀式，宣佈各方將在資源整合，模式創新等層面持續合作，探索更多適配於大灣區的醫療保險產品與服務。在隨後的圓桌論壇環節，由鎂信健康首席商務官郎立良先生擔任主持人，與尚志醫療集團醫務行政總監、外科專科醫生郭寶賢先生，中國太平洋人壽（香港）聯席行政總裁、香港精算學會（ASHK）前主席、現任理事Simon Lam先生，香港精算視覺保險學會會長、大灣區保險學院聯合創始人牟劍群先生，以及諾華香港的相關代表深入探討大灣區醫療保融合的各方實踐。各位嘉賓從不同角度分享了對大灣區醫療保險發展的見解與建議，探討了如何加強大灣區醫療保障合作、提升醫療服務水準、促進保險產品創新等關鍵問題。鎂信健康在論壇中積極發聲，提出通過公立+特需/私立結合、資源整合等方式，賦能醫療資源的互補和互通，推動大灣區醫療保險服務的升級與優化，為大灣區居民提供更加優質的醫療保障體驗，得到了與會嘉賓的廣泛認可與支持。「服務國家戰略，共建健康灣區」發佈儀式凝聚信心 攜手同行論壇壓軸環節，中國太平洋人壽保險原董事長、大家保險集團原總經理徐敬惠先生發表主旨發言。他從行業發展的宏觀角度，對大灣區醫療保險的未來發展進行了深入分析與展望，總結出三個"心"的感受。首先是信心，近年來，在各項政策的推動下，大灣區醫療互聯互通成效明顯，多項跨境醫療福利成功"過河"，跨境醫療的"民生流量"也在政策協同的推動下持續升溫，這讓我們對未來充滿信心。第二個是"初心"，徐敬惠先生強調，"以人民健康為中心"的初心，是破解難題的指南針。最後是"同心"，不管是中再、鎂信，還是醫療、醫藥機構，都在各自領域搭建著連通橋，各方攜手共同推動大灣區醫療保險事業的發展，為大灣區居民的健康保駕護航。此次論壇發佈的"灣區跨境醫療解決方案"，鎂信健康深度參與並提供特藥支持。它打破了地域壁壘，整合了兩地資源，為跨境醫療服務的標準化、一體化樹立了典範。這種合作模式不僅提升了居民的健康保障體驗，也為行業探索出了一條可持續發展的新路。本次粵港澳大灣區醫療保險發展論壇的順利舉行，不僅推動了灣區保險行業對跨境醫療議題的深度關注，也為後續創新與產業協作奠定了良好基礎。鎂信健康作爲參與方之一，將持續深耕大灣區，攜手更多夥伴推進醫療保障數智化轉型，助力實現健康灣區的美好願景。 Copyright 2025 亞太商訊 via SeaPRwire.com.

Starter Deck 03 ‘Ω to the Future’ marks the highly anticipated debut of Ultraman Omega in card form, featuring exclusive cards and brand new strategies that bring the latest TV series to life and allowing fans to experience the title hero’s journey.Booster Pack 04 ‘Gleam of Eternal Hope’ introduces powerful new versions of iconic Ultra Heroes including Ultraman Dyna, Z, and Trigger. These upgraded cards unlock expanded tactical possibilities, reshaping the game and delivering fresh competitive angles for seasoned players.With the release of both new sets as well as the return of fan-favourite ExP (Extra Parallel) rarity cards, and momentum building toward the Ultra League World Championship 2026, the Ultraman Card Game is poised to grow its global fanbase and strengthen its presence within the trading card game community.KUALA LUMPUR, July 25, 2025 - (ACN Newswire via SeaPRwire.com) - Tsuburaya Productions unveils today the latest additions to the ever-popular Ultraman Card Game - Starter Deck 03 ‘Ω to the Future’ and Booster Pack 04 ‘Gleam of Eternal Hope’, launching globally on Friday, 25 July 2025 and Friday, 1 August 2025 respectively. These upcoming game sets build on the momentum of the newly launched Ultraman Omega television series, as well as beloved characters such as Ultraman Arc, whilst introducing brand-new gameplay mechanics, evolution strategies and dynamic synergies centred around these iconic Ultra Heroes. Ultraman Omega Makes His First-Ever Card Game AppearanceA highlight of the new Starter Deck 03 ‘Ω to the Future’ is the much-anticipated debut of Ultraman Omega in card form. This new deck draws inspiration from the ongoing Ultraman Omega television series, which premiered in Japan earlier this month.Reflecting the show’s narrative, the deck features exclusive cards from the Ultraman Omega series, including the titular Ultraman Omega, Meteokaiju, and fan-favourite Giants of Light such as Ultraman Arc. These new cards introduce fresh gameplay mechanics that reward strategic thinking and foresight, from granting power boosts when fielding characters of the same type to enabling tactical card rotations that encourage smarter deck management. With these new mechanics and play styles, players can look forward to reliving key story moments and experiencing Ultraman Omega’s growth firsthand.As an added early-release bonus, players will also be able to receive a bonus pack of Booster Pack 04 ‘Gleam of Eternal Hope’ for every purchase of Starter Deck 03 ‘Ω to the Future’, offering fans an early taste of the upcoming expansion and even more ways to power up their decks.Fan-Favourite Heroes Return with Upgraded PowersBooster Pack 04 ‘Gleam of Eternal Hope’ continues to expand the strategic possibilities of the game, featuring powerful upgraded cards for popular Ultra Heroes including Ultraman Dyna, Ultraman Z, and Ultraman Trigger.These upgrades introduce new abilities that not only refresh existing decks but also deepen tactical options across competitive formats. With a more extensive card pool, players can look forward to more creative deckbuilding strategies that are sure to influence the current approach to gameplay.Collectors Rejoice: ExP (Extra Parallel) Cards Make a ReturnBack by popular demand, the ExP (Extra Parallel) rarity cards - first introduced in Booster Pack 02 ‘Vortex of Crimson and Azure’ - make a dazzling return in ‘Gleam of Eternal Hope’.These collector-favourite cards are known for their exclusive full-art illustrations, premium foil finish, and elegant gold framing. Scheduled to be revealed on Friday, 1 August 2025, ‘Gleam of Eternal Hope’ will see the addition of two brand-new types of ExP card, offering high visual appeal and collectability for long-time fans and new enthusiasts alike.Exclusive Box Topper: Alien Baltan The Space NinjaAdding to the excitement, each 24-pack box of ‘Gleam of Eternal Hope’ will include a special box topper card featuring Alien Baltan, one of the most iconic villains in Ultraman history.This unique card mirrors Baltan’s illusory powers, allowing an unlimited number of copies to be included in a single deck - a rare and rule-breaking mechanic. The artwork captures the classic scene of Baltan duplicating itself and unleashing its signature red freezing ray, leveraging nostalgia for long-term fans.Fans in Malaysia can look forward to purchasing the English-language Starter Deck 03 ‘Ω to the Future’ at MYR 46.00 and Booster Pack 04 ‘Gleam of Eternal Hope’ in either individual packs at MYR 18.00 or as a 24-pack box at MYR 432.00 at authorised hobby stores, major retailers, and online platforms.These releases are poised to equip both new and veteran Ultra Leaguers with competitive decks ahead of major events, including the upcoming inaugural Ultra League World Championship 2026, set to take place on 9 and 10 May 2026 in Tokyo, Japan. This prestigious tournament will see players from around the world battling through regional qualifiers for a shot at the title of world’s best Ultra Leaguer, with exclusive cards and gameplay accessories up for grabs. For more information on the Ultraman Card Game, please refer to https://ultraman-cardgame.com/page/my/top.About Tsuburaya ProductionsTsuburaya Productions is a global entertainment company providing content, products and services full of creativity and innovation. Since the airing of Ultra Q and Ultraman in 1966, the company has continued to create characters and stories that are loved by fans worldwide.TSUBURAYA PRODUCTIONS Official Global Site: https://tsuburaya-prod.com/Ultraman Card Game Official Website: https://ultraman-cardgame.com/About Ultraman Card GameThe Ultraman Card Game is a dynamic trading card game developed by Tsuburaya Productions, bringing the iconic Ultraman universe to life through strategic gameplay and collectible cards. Designed for fans of all ages, the game features high-quality artwork showcasing Ultraman's heroes, kaiju, and special moves, offering both engaging play and collectibility. With simultaneous releases in multiple languages across various regions, the Ultraman Card Game invites players around the world to explore the rich legacy of Ultraman, engage in epic battles, and grow their collections. Copyright 2025 ACN Newswire via SeaPRwire.com.

SHANGHAI, July 25, 2025 - (ACN Newswire via SeaPRwire.com) - Everest Medicines (HKEX 1952.HK, “Everest” or the “Company”), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it has entered into a placing and subscription agreement with the placing agents and its controlling shareholder, CBC Group (the “Sellers”), for a top-up placement of 22,561,000 shares to raise approximately HK$1,572.50 million, representing approximately 6.87% of the total number of Shares in issue as at the date of this announcement, and approximately 6.45% of the total number of Shares in issue.Everest Medicines, together with its controlling shareholder CBC Group and the placing agents, entered into a placing and subscription agreement for the sale of 22,561,000 shares at a purchase price of HK$69.70 per share, representing:- a discount of approximately 10.12% to the closing price of HK$77.55 per share on July 24, 2025.- a discount of approximately 4.98% to the average closing price of HK$73.35 per Share as quoted on the Stock Exchange for the five consecutive trading days immediately prior to and including the Last Trading Date.- a premium of 16.15% to the volume weighted average price of HK$60.01 per Share as quoted on the Stock Exchange for the thirty consecutive trading days immediately prior to the Last Trading Date and including the Last Trading Date.The gross proceeds from the Placing and Subscription are expected to be approximately HK$1,572.50 million, and the net proceeds (after deducting all related expenses, including commission and levies) will be approximately HK$1,553.39 million.Everest Medicines intends to use approximately 50% of the net proceeds (approximately HK$776.69 million) to support global research and development of pipeline products, approximately 40% (approximately HK$621.36 million) to commercialization efforts including the launch of new products, and 10% (approximately HK$155.34 million) to working capital and general corporate purposes.“This placement was well-received by several leading international long-only funds and was significantly oversubscribed, reflecting strong capital market confidence in Everest’s commercial execution capabilities and innovative R&D strengths,” said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. “It also underscores investors’ endorsement of our long-term strategic vision. We will use the proceeds to accelerate the development of innovative pipelines and our proprietary AI+mRNA platform, while advancing the commercialization of our existing portfolio. With a strengthened capital base, we are poised to drive both commercialization and innovation, delivering greater value to patients and shareholders.”Everest has built an industry-leading, fully integrated, and localized AI+mRNA platform, enabling the development of multiple oncology and autoimmune disease programs, including EVM14, an off-the-shelf therapeutic mRNA cancer vaccine; EVM16, a personalized mRNA cancer vaccine; and an in vivo CAR-T program aimed at building a differentiated portfolio of precision immunotherapies.- The first patient has been dosed with Everest’s internally developed personalized mRNA cancer vaccine (PCV) EVM16 at Peking University Cancer Hospital in the investigator-initiated clinical trial (IIT). Early results showed strong immunogenicity and specific T-cell responses even at a low starting dose in advanced cancer patients.- The Investigational New Drug (IND) application for EVM14, a Tumor-Associated Antigen (TAA) vaccine, has been accepted by both the National Medical Products Administration (NMPA) of China and the U.S. Food and Drug Administration (FDA), making it Everest's first mRNA cancer therapeutic vaccine to achieve dual IND submissions in both China and the United States. The first clinical batch of EVM14 was successfully released from Everest’s Jiashan manufacturing site on June 9, and is anticipated to be delivered to U.S. clinical centers by mid-August. This batch will support the clinical trials of EVM14 in both China and the United States (US).- Everest’s in vivo CAR-T program is founded upon its proprietary targeted LNP (tLNP) delivery system and has shown promising results in both humanized mouse models and non-human primates. It offers key advantages including off-the-shelf availability, lymphodepletion-free administration, and dose controllability.EVER001, a next-generation covalent reversible BTK inhibitor with global rights, is advancing through global multi-center clinical studies for glomerular diseases such as primary membranous nephropathy (pMN). Positive results from its Phase 1b/2a clinical trial demonstrated rapid onset, durable response, good tolerability, and oral convenience, offering strong potential to address unmet needs in renal disease treatment worldwide.NEFECON®, the first and only etiological treatment for IgA nephropathy (IgAN) full approved in China, the U.S., and Europe, continues to gain strong commercial traction in China following its inclusion in the National Reimbursement Drug List (NRDL), benefiting over 20,000 patients to date. Everest is also accelerating the development of its proprietary diagnostic test for Gd-IgA1 to build an integrated disease management ecosystem encompassing diagnosis, treatment, and long-term care.The New Drug Application (NDA) for Etrasimod (VELSIPITY®) has been accepted in Mainland China, with approval anticipated between late 2025 and early 2026. The NDA has also been accepted in South Korea. VELSIPITY® has been commercially launched in Macao SAR, Singapore and Hong Kong SAR in 2024. As Everest’s third commercialized product, VELSIPITY® has been officially approved by the Guangdong Provincial Medical Products Administration for adult patients with moderately to severely active UC. It is now available at medical institutions designated under the Connect Policy in the Greater Bay Area. In March 2025, Everest has launched the construction project at its Jiashan manufacturing site to support the local production for VELSIPITY®.Everest Medicines is accelerating the strategic advancement of its core pipeline and AI+mRNA technology platforms to further solidify its position as a leading innovative biopharmaceutical company in Asia.About Everest MedicinesEverest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines that address critical unmet medical needs for patients in Asian markets. The management team of Everest Medicines has deep expertise and an extensive track record from both leading global pharmaceutical companies and local Chinese pharmaceutical companies in high-quality discovery, clinical development, regulatory affairs, CMC, business development and operations. Everest Medicines has built a portfolio of potentially global first-in-class or best-in-class molecules in the company’s core therapeutic areas of renal diseases, infectious diseases and autoimmune disorders. For more information, please visit its website at www.everestmedicines.com.Forward-Looking Statements:This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law. Copyright 2025 ACN Newswire via SeaPRwire.com.